VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data

Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.

Share
Veru chief executive Mitchell Steiner leads the company's oncology and cardiometabolic pipeline.